Live price temporarily unavailable.
RenovoRx (RNXT) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | $43.0K | $1.12M |
| Growth (year over year) | — | — | — | — | — | +2511.6% |
| Gross profit | — | — | — | — | $43.0K | $796.0K |
| Gross margin | — | — | — | — | 100.0% | 70.9% |
| Operating income | −$3.20M | −$5.67M | −$9.95M | −$11.4M | −$11.0M | −$12.5M |
| Operating margin | — | — | — | — | −25511.6% | −1114.0% |
| Net income | −$3.80M | −$6.32M | −$9.89M | −$10.2M | −$8.81M | −$11.2M |
| Net margin | — | — | — | — | −20497.7% | −994.5% |
| EPS (diluted) | −$1.72 | −$1.21 | −$1.09 | −$0.99 | −$0.40 | −$0.32 |
| Balance sheet | ||||||
| Cash and equivalents | $1.79M | $15.2M | $4.39M | $1.17M | $7.15M | $7.02M |
| Total assets | $1.91M | $16.3M | $7.26M | $1.47M | $8.12M | $8.10M |
| Total liabilities | $4.12M | $938.0K | $1.10M | $4.47M | $3.64M | $2.67M |
| Shareholders' equity | −$14.7M | $15.3M | $6.16M | — | $4.48M | $5.42M |
| Cash flow | ||||||
| Operating cash flow | −$3.53M | −$5.92M | −$8.81M | −$10.3M | −$9.13M | −$11.0M |
| Capital expenditure | — | — | — | — | $12.0K | $2.00K |
| Free cash flow | — | — | — | — | −$9.14M | −$11.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $197.0K | $422.0K | $266.0K | $238.0K | $563.0K | $909.0K |
| Growth (year over year) | — | — | — | — | — | — | +185.8% | +115.4% |
| Gross profit | — | — | $103.0K | $270.0K | $213.0K | $210.0K | $479.0K | $766.0K |
| Gross margin | — | — | 52.3% | 64.0% | 80.1% | 88.2% | 85.1% | 84.3% |
| Operating income | −$2.83M | −$2.63M | −$3.11M | −$2.68M | −$3.20M | −$3.52M | −$3.47M | −$3.35M |
| Operating margin | — | — | −1578.7% | −634.6% | −1203.0% | −1479.8% | −616.2% | −368.4% |
| Net income | −$2.47M | −$2.88M | −$2.42M | −$2.90M | −$2.91M | −$2.94M | −$3.52M | −$2.91M |
| Net margin | — | — | −1228.4% | −686.0% | −1094.7% | −1235.7% | −625.4% | −320.2% |
| EPS (diluted) | −$0.10 | −$0.13 | −$0.08 | −$0.08 | −$0.08 | −$0.08 | −$0.09 | −$0.06 |
| Balance sheet | ||||||||
| Cash and equivalents | $9.56M | $7.15M | $14.6M | $12.3M | $10.0M | $7.02M | $12.4M | $9.48M |
| Total assets | $10.0M | $8.12M | $16.0M | $13.6M | $11.2M | $8.10M | $14.0M | $11.5M |
| Total liabilities | $2.96M | $3.64M | $2.86M | $3.00M | $3.13M | $2.67M | $2.70M | $2.49M |
| Shareholders' equity | $7.07M | $4.48M | $13.2M | $10.6M | $8.08M | $5.42M | $11.3M | $8.98M |
| Cash flow | ||||||||
| Operating cash flow | −$2.19M | −$2.43M | −$3.38M | −$2.30M | −$2.27M | −$3.02M | −$3.71M | −$2.87M |
| Capital expenditure | — | — | $2.00K | $0 | $0 | $0 | $0 | $71.0K |
| Free cash flow | — | — | −$3.38M | −$2.30M | −$2.27M | −$3.02M | −$3.71M | −$2.94M |
From RenovoRx's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning RenovoRx in our feed yet.